Ninety One North America Inc. Takes $7.07 Million Position in Eli Lilly and Company $LLY

Ninety One North America Inc. purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 6,581 shares of the company’s stock, valued at approximately $7,072,000.

Several other institutional investors have also recently made changes to their positions in the company. Ninety One SA Pty Ltd purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at $645,000. Werba Rubin Papier Wealth Management increased its stake in shares of Eli Lilly and Company by 17.2% during the fourth quarter. Werba Rubin Papier Wealth Management now owns 799 shares of the company’s stock valued at $859,000 after buying an additional 117 shares during the period. Moran Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 3.5% during the fourth quarter. Moran Wealth Management LLC now owns 10,613 shares of the company’s stock valued at $11,406,000 after buying an additional 362 shares during the period. Tanager Wealth Management LLP increased its stake in shares of Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after buying an additional 10 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC increased its stake in shares of Eli Lilly and Company by 8.6% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 1,675 shares of the company’s stock valued at $1,800,000 after buying an additional 133 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $903.54 on Wednesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The firm has a market capitalization of $853.68 billion, a price-to-earnings ratio of 39.37, a PEG ratio of 1.07 and a beta of 0.51. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The stock’s 50-day simple moving average is $966.24 and its 200-day simple moving average is $984.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the previous year, the firm earned $5.32 earnings per share. The company’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 34.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LLY has been the topic of several research reports. CICC Research raised their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Jefferies Financial Group set a $1,300.00 price target on Eli Lilly and Company and gave the company a “buy” rating in a research note on Friday, March 13th. Freedom Capital upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Cantor Fitzgerald raised their price target on Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Finally, Royal Bank Of Canada started coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,224.59.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly announced a deal to acquire Kelonia Therapeutics in a transaction worth up to $7 billion (about $3.25B upfront), adding an in?vivo CAR?T platform and an early?stage multiple myeloma program to its genetic?medicine/oncology pipeline — a strategic diversification beyond GLP?1s that supports long?term growth expectations. Lilly to acquire Kelonia Therapeutics (PR Newswire)
• Positive Sentiment: Analysts view the Kelonia purchase as a strategic bet on next?generation in?vivo CAR?T; UBS maintained a Buy with a $1,250 target, highlighting pipeline upside that could materially expand Lilly’s long?term addressable market. MSN: Eli Lilly doubles down on in vivo with $7bn Kelonia buyout
• Neutral Sentiment: Lilly formally ended a prior collaboration with Rigel Pharmaceuticals; Rigel says it has regained rights to the program. This is more of a portfolio cleanup than a material pipeline loss for Lilly, but it removes optionality tied to that partnership. Rigel regains rights as Lilly ends collaboration
• Neutral Sentiment: A court ruled Eli Lilly can proceed with a lawsuit against a telehealth seller of weight?loss drugs — the case could protect Lilly’s commercial and IP interests but is ongoing and uncertain in outcome. Court allows Lilly lawsuit to proceed (Courthouse News)
• Negative Sentiment: Competitive and distribution risks are pressuring sentiment: coverage highlights Amazon’s moves into GLP?1 distribution, which could increase price/volume pressure in Lilly’s high?margin weight?loss franchise. This helped weigh on the stock despite the acquisition. How Amazon is shaking up the GLP?1 game (Yahoo)
• Negative Sentiment: Near?term market reaction: coverage and trading notes show LLY pulled back more than the market on these headlines as investors weigh the near?term cash outflow, dilution of focus from blockbuster GLP?1s, and competitive risks. Zacks: LLY declines more than market

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.